Digital Spatial Profiling Links Beta-2-microglobulin Expression with Immune Checkpoint Blockade Outcomes in Head and Neck Squamous Cell Carcinoma.
Journal
Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
28
07
2022
revised:
02
11
2022
accepted:
03
03
2023
medline:
15
4
2023
entrez:
14
4
2023
pubmed:
15
4
2023
Statut:
epublish
Résumé
Programmed cell death protein-1 (PD-1)-targeted immunotherapy is approved for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treatment. Although its efficacy correlates with PD-L1 expression, response is limited even among positive cases. We employed digital spatial profiling (DSP) to discover potential biomarkers of immunotherapy outcomes in HNSCC. Fifty prospectively collected, pretreatment biopsy samples from patients with anti-PD-1-treated R/M HNSCC, were assessed using DSP, for 71 proteins in four molecularly defined compartments (tumor, leukocyte, macrophage, and stroma). Markers were evaluated for associations with progression-free (PFS) and overall survival (OS). High beta-2 microglobulin (B2M), LAG-3, CD25, and 4-1BB in tumor; high B2M, CD45, CD4 in stroma, and low fibronectin in the macrophage compartment, correlated with prolonged PFS. Improved PFS and OS were observed for cases with high B2M by quantitative and mRNA. Findings were validated in an independent cohort for PFS (HR, 0.41; 95% confidence interval, 0.19-0.93; In the current study, DSP revealed the positive association of B2M expression in the tumor compartment with immunotherapy outcomes in R/M HNSCC.
Identifiants
pubmed: 37057033
doi: 10.1158/2767-9764.CRC-22-0299
pii: CRC-22-0299
pmc: PMC10088911
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
558-563Subventions
Organisme : NIDCR NIH HHS
ID : P50 DE030707
Pays : United States
Informations de copyright
© 2023 The Authors; Published by the American Association for Cancer Research.
Références
Cancer Immunol Immunother. 2017 Feb;66(2):259-271
pubmed: 28040849
Methods Mol Biol. 2020;2055:563-583
pubmed: 31502169
Nat Commun. 2017 Oct 26;8(1):1136
pubmed: 29070816
J Immunother Cancer. 2022 Feb;10(2):
pubmed: 35217573
Annu Rev Immunol. 2019 Apr 26;37:173-200
pubmed: 30550719
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Cancer Treat Rev. 2020 Mar;84:101977
pubmed: 32018128
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514
pubmed: 32442275
Cancer Discov. 2017 Dec;7(12):1420-1435
pubmed: 29025772
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Cancer Res. 2006 Sep 15;66(18):9281-9
pubmed: 16982773
J Clin Med. 2019 Nov 07;8(11):
pubmed: 31703248
Clin Cancer Res. 2021 Apr 1;27(7):1987-1996
pubmed: 33504554
Clin Cancer Res. 2005 Apr 1;11(7):2552-60
pubmed: 15814633
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Oral Oncol. 2018 Jun;81:45-51
pubmed: 29884413
Br J Cancer. 2008 Nov 4;99(9):1453-61
pubmed: 18841160
Mod Pathol. 2021 Mar;34(3):532-541
pubmed: 33239737
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740